Trial Profile
A Multicenter, Open Label, Pilot Study to Investigate Tolerability and Efficacy of MK5172 / MK8742 Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection With Compensated Cirrhosis (Child-Pugh A5 to A6) and No Response to PR or Prior Failure to First Generation Protease Inhibitors (PIs)
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 10 Mar 2022
Price :
$35
*
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms GECOM
- 10 Mar 2022 This trial has been discontinued in Italy according to European Clinical Trials Database record.
- 11 Apr 2016 New trial record